The First Tranche consisted of 13,940,000 units ("Units") at a price of $0.10 per Unit for aggregate gross proceeds of $1,394,000. Each Unit consists of one common share of the Company (each a "Share") and one-half of one common share purchase warrant (each whole warrant, a "Warrant"). Insider ParticipationInsiders of the Company purchased an aggregate of 1,900,000 Units in the First Tranche for aggregate gross proceeds of $190,000. About Rakovina Therapeutics Inc.Rakovina Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. Notice Regarding Rakovina Therapeutics Forward-Looking Statements:This release includes forward-looking statements regarding the company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the company and other statements.